BTG makes good progress

LONDON (SHARECAST) - Medical innovations outfit BTG said it has made good progress in the first nine months of the year, performing in line with expectations since last October’s update.

In addition, recruitment of patients in the phase II safety study of Varisolve, a treatment for varicose veins without surgery, is on track for the planned finish by June 2008.

Full-year expenditure is anticipated to be in the range £12-14m, while operating and administrative costs are stable and are seen at around £18-19m.

“Over the coming months we expect to report results from our sleep apnoea and head lice clinical studies, initiate the first clinical studies for our migraine and MS programmes, and conclude the US safety study of Varisolve,” said chief executive Louise Makin.